Post TAVR AVB: Is Telemetry Monitoring Necessary?

Original Title: The Electrocardiogram after Transcatheter Aortic Valve Replacement Determines the Risk for Post-Procedural High-Degree AV Block and the Need for Telemetry Monitoring Reference: J Am Coll Cardiol Intv. 2016;9(12):1269-1276.   Courtesy of Dr. Agustín Vecchia. So far, we have not been able to determine the moment high degree atrioventricular block (AVB) takes place after<a href="https://solaci.org/en/2016/07/22/post-tavr-avb-is-telemetry-monitoring-necessary/" title="Read more" >...</a>

Medtronic’s New CoreValve Evolut R for TAVR

Original Title: Treatment of Symptomatic Severe Aortic Stenosis with a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. Reference: Ganesh Manoharan et al. J Am Coll Cardiol Intv. 2015; 8(10):1359-1367.   Courtesy of Dr. Agustín Vecchia. Despite the rapid growth and evolution of transcatheter aortic valve replacement devices (TAVR), vascular access complications, paravalvular leak, stroke<a href="https://solaci.org/en/2016/07/08/medtronics-new-corevalve-evolut-r-for-tavr/" title="Read more" >...</a>

Extreme Valve Calcification in TAVI might compromise technical success

Original Title: Ballon-Expandable Trancatheter Aortic valve Replacement in Patients whit Extreme Aortic Valve Calcification. Reference: Yigal Abramowitz, et al. Catetherization and Cardiovascular Intervention 2016;87:117-1179.   Courtesy of Dr. Carlos Fava.   Transcatheter aortic valve replacement (TAVI) emerged as a valid option to treat high risk inoperable patients. A group of these patients presents extreme valve<a href="https://solaci.org/en/2016/06/16/extreme-valve-calcification-in-tavi-might-compromise-technical-success/" title="Read more" >...</a>

Low risk patients: TAVI or surgical replacement?

Original Title: Transcatheter Aortic Valve Implantation Compared With Surgical Aortic Valve Replacement in Low-Risk Patients. Reference: Stefano Rosato et al. Circ Cardiovasc Interv. 2016 May;9(5):e003326. The proved efficacy of transcatheter aortic valve implantation (TAVI) in high risk patients is leading the expansion of its indication for lower risk patients. All the same, compared to the<a href="https://solaci.org/en/2016/05/27/low-risk-patients-tavi-or-surgical-replacement/" title="Read more" >...</a>

Favorable Outcomes with New Generation Transcatheter Heart Valves in Bicuspids

Original Title: Bicuspid Aortic Valve Stenosis Favorable Early Outcomes UIT a Next-Generation Transcatheter Heart Valve in a Multicenter Study. Reference: Gidon Y. Perlman J Am Coll Cardiol Interv 2016;9:817-24 Courtesy of Dr. Carlos Fava. Congenital bicuspid aortic valves are infrequent and are associated with severe calcification in elderly patients. Transcatheter aortic valve replacement to treat bicuspid<a href="https://solaci.org/en/2016/04/27/favorable-outcomes-with-new-generation-transcatheter-heart-valves-in-bicuspids/" title="Read more" >...</a>

TAVR with Sapien XT: similar to surgical replacement in intermediate risk patients

Original Title: Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. PARTNER 2A. Reference: Martin B. Leon et al. NEJM April 2, 2016 Courtesy of Dr. Juan A. Terré Studies have shown mortality rates after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in high risk patients are similar (PARTNER 2 – Cohort B). This is<a href="https://solaci.org/en/2016/04/15/tavr-with-sapien-xt-similar-to-surgical-replacement-in-intermediate-risk-patients/" title="Read more" >...</a>

TAVI in Low-Flow / Low-Gradient

Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a<a href="https://solaci.org/en/2016/04/14/tavi-in-low-flow-low-gradient/" title="Read more" >...</a>

TAVI: Good Outcomes with Intermediate Risk

Original Title: Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement in Intermediate-Risk Patients: A Propensity Score Analysis. Reference: Vinod H Thourani et al. Lancet Published Online April 3, 2016. Courtesy of Dr. Carlos Fava. The transcatheter Aortic Valve Replacement (TAVI) has shown benefits in high risk patients or inoperable patients, but there is little evidence<a href="https://solaci.org/en/2016/04/13/tavi-good-outcomes-with-intermediate-risk/" title="Read more" >...</a>

The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study

The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN 3 valve showed lower rates of death, stroke and paravalvular leak at one year than patients undergoing surgery. This third generation improves the SAPIEN XT with a skirt designed to prevent<a href="https://solaci.org/en/2016/04/08/the-sapien-3-valve-resulted-superior-to-surgery-in-an-observational-study/" title="Read more" >...</a>

CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery

At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery. These findings could suggest that the self-expanding valve should be considered the preferred treatment in patients with symptomatic severe aortic stenosis at increased risk for surgery. The study included 797 patients<a href="https://solaci.org/en/2016/04/08/corevalve-us-pivotal-at-3-years-the-self-expanding-valve-maintains-its-advantage-vs-surgery/" title="Read more" >...</a>

pacemaker